Jennifer Buell, Ph.D.Chief Executive Officer
Dr. Buell serves as the Chief Executive Officer at Agentus and as President and Chief Operating Officer at Agenus, where she is responsible for organizational operations, including Research, Clinical Development, Manufacturing, Commercial Operations, Communications, Investor Relations and External Affairs. Since joining Agenus in 2013, Dr. Buell has served as the Head of Global R&D operations, Head of Research, and Chief Communications and External Affairs Officer. During her tenure, she helped advance the expansion of Agenus from a neoantigen vaccine company to a global, fully-integrated platform company with a unique pipeline of immune modulating antibodies, cancer vaccines, adjuvants, and adoptive cell therapies. With 20 years of biopharmaceutical R&D experience, Jennifer has extensive knowledge in advancing discovery candidates through development and experience communicating with external stakeholders including regulators, investors, and collaborators. She has a proven record of success in R&D leadership, most recently at Agenus, where she led high performing teams in advancing candidates into the clinic and delivered on key alliance collaborations. Prior to joining Agenus, Jennifer held leadership positions in R&D operations at Bristol-Myers Squibb and later was responsible for Program and Alliance Management at Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government sponsored clinical programs. Jennifer obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.
Marc Van Dijk, PhDChief Technology Officer
Marc van Dijk, Ph.D. leads platform development for AgenTus, and currently serves as Chief Technology Officer at Agenus. Previously, he served as Chief Technology Officer of 4-Antibody, a subsidiary of Agenus, where he oversaw the development of Retrocyte Display™, Agenus’ proprietary antibody discovery platform. In this role, Dr. van Dijk led the antibody discovery programs in the alliance with the Ludwig Institute for Cancer Research branch in New York, including the CTLA4, PD1, GITR and OX40 programs, the resulting antibodies of which are now in clinical development. Dr. van Dijk was Vice President, Antibody Technology at Genmab, and Director of Applied Research at Innogenetics (now Fujirebio) During his time at Medarex and Genmab, he was involved in the set up and management of partnerships with Immunex (now Amgen), and Roche, and served as project leader on numerous discovery projects including Humax-CD20 (Arzerra™, Novartis). Dr. van Dijk held a tenure track position in the Department of Immunology at the University Medical Center in Utrecht and completed his postdoctoral fellowship in Molecular Biology at the University of California, San Diego. He obtained his Ph.D. in Molecular Biology from Utrecht University in 1992.
Patrick JordanChief Operating Officer
Prior to joining AgenTus Therapeutics as its Chief Operating Officer, Patrick Jordan served as Vice President Global Distributor Markets at Amryt Pharma. Mr. Jordan has also served in various commercial leadership positions at Wyeth, Pfizer, and MSD, and has considerable P&L management and market access experience throughout Europe, LATAM, Canada, Russia/CIS, and the Middle East. In the Middle East in particular, he has had multiple successes in large-scale vaccine procurement, institutional procurement, and named patient procurement. He brings to AgenTus over 20 years of industry experience, spanning primary care, specialty care, immuno-oncology, and rare disease. Mr. Jordan holds a BA in Biochemistry/Molecular Biology from Boston University and an MBA from Babson College.